Sort by
Refine Your Search
-
Listed
-
Category
-
Country
-
Program
-
Field
-
ability to apply fundamental nursing assessment and triage via telephone, electronic systems and in person to patients receiving chemotherapy, biotherapy and/or stem cell transplant Demonstrated knowledge
-
, optogenetics, genome engineering, induced pluripotent stem cell differentiation to neurons/organoids, and in vitro and in vivo electrophysiological measurements. Our long-term scientific goal is to dissect
-
genomics, transcriptomics, and epigenomics with mechanistic studies using in vitro and in vivo models to dissect B-ALL and related hematologic malignancies. The lab also studies normal hematopoietic stem
-
. Dynamic preservation using perfusion machines allows control of IR, and we have demonstrated the efficacy of a cellular therapy derived from urine progenitor cells. Despite the protective and promising
-
University of North Carolina at Chapel Hill | Chapel Hill, North Carolina | United States | about 1 month ago
. The goals of the Rich Lab are to identify novel therapeutic paradigms in the treatment of advanced cancers, primarily malignant brain tumors, through the prism of stem cell biology to identify core regulatory
-
intervention systems; digital healthcare systems; real-time physiological monitoring technologies; multimodal data integration and analysis for imaging and sensing. Human Centered Models and Systems: human stem
-
Institute of Animal Reproduction and Food Research of Polish Academy of Sciences | Poland | 2 months ago
Responsibilities • Isolation of CD34⁺ hematopoietic stem and progenitor cells from cord blood donors for in vitro studies. • Preparation of RNA and chromatin libraries for NGS (RNA-seq, ATAC-seq, ChIPmentation
-
Therapies Donor Services Specialist facilitates allogeneic donor identification and collection processes on behalf of adult and pediatric patients undergoing a stem cell transplant or other Cellular Therapy
-
the liver microenvironment. Experiments will utilize animal models, cell culture including induced pluripotent stem cells, and human patient samples. Required Qualifications: Applicants should hold a PhD
-
Leukemia DC15: Novel preclinically-validated GATA3 inhibitor/degrader as a therapy for T-cell Acute Lymphoblastic Leukemia DC16: Targeting Metabolic Pathways in Leukemic Stem Cells for AML Treatment